EGFR and thyroid gland carcinoma: The pathways that are most frequently identified by hypergeometric test but not by weighted resampling include hsa04360: axon guidance (6/26 samples) and hsa05216: thyroid cancer (5/26 samples), followed by hsa04010: MAPK signaling pathway and hsa04012: ErbB signaling pathway in 4 samples, and all the others in less than 4 samples.